dpp-4 inhibitor and glp-1 receptor agonist combination not recommended guideline versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes The effect of DPP-4 inhibitors,

Learn how GLP-1 drugs can help you lose weight, which ones are best, and where to get them.

With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management

Here, we provide a comprehensive review of the therapeutic potential of incretin mimetics and insulin in AD and PD.

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.

From weight loss breakthroughsto type 2 diabetes management, and even anti-aging medicine, these treatments offer extraordinary promise.But with innovation comes risk

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection